Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Trading Up 18.8 %

Shares of Accelerate Diagnostics stock opened at $1.39 on Tuesday. The firm has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $1.54. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $2.09. The stock has a market capitalization of $34.81 million, a price-to-earnings ratio of -0.49 and a beta of 0.59.

Insider Buying and Selling at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience bought 200,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were bought at an average cost of $1.57 per share, for a total transaction of $314,000.00. Following the transaction, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 43.60% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics as of its most recent filing with the Securities and Exchange Commission. 17.14% of the stock is owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.